Monitoring Patient Access to Family-Based Opioid Use Disorder Treatment in New Jersey

Brief

Monitoring Patient Access to Family-Based Opioid Use Disorder Treatment in New Jersey

Abstract

Expanding access to effective treatment for opioid use disorder (OUD) is essential to staunching the opioid epidemic. This brief is one of the first studies to assess patient access to treatment services for OUD at facilities that offer OUD pharmacotherapy across New Jersey. We conducted phone surveys in 2018 with substance use treatment facilities in New Jersey. This brief presents data about specific treatment service availability, wait times, and Medicaid coverage of treatment, including region- and county-specific data to assess the supply and demand of various treatment options throughout New Jersey. We estimate that only 49 percent of substance use treatment facilities offered any form of OUD pharmacotherapy—buprenorphine, methadone, or naltrexone. Overall, patients had a median wait time of two days for both regular and intensive outpatient services, but wait times varied widely across both county and service type.
Research Area: 

Centers

To reuse content from Urban Institute, visit copyright.com, search for the publications, choose from a list of licenses, and complete the transaction.
LATEST IN Health and Health Policy
To reuse content from Urban Institute, visit copyright.com, search for the publications, choose from a list of licenses, and complete the transaction.